UBS analyst Ashwani Verma downgraded Crinetics (NASDAQ: CRNX) from Buy to Neutral with a price target of $85.00 (from $55.00).The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE